27392220|t|Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy
27392220|a|Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.
27392220	12	29	Cancer Stem Cells	T025	C1956422
27392220	33	36	CML	T191	C0023473
27392220	54	69	Transcriptional	T045	C0040649
27392220	70	77	Therapy	T061	C0087111
27392220	78	86	Leukemia	T191	C0023418
27392220	87	97	stem cells	T025	C1956422
27392220	99	103	LSCs	T025	C1956422
27392220	130	139	therapies	T061	C0087111
27392220	154	178	chronic myeloid leukemia	T191	C0023473
27392220	180	183	CML	T191	C0023473
27392220	226	243	molecular network	T044	C1148560
27392220	244	252	critical	T169	C0231242
27392220	257	260	CML	T191	C0023473
27392220	261	264	LSC	T025	C1956422
27392220	265	273	survival	T043	C0007620
27392220	335	361	transcriptional regulators	T116,T123	C0040648
27392220	363	366	p53	T028	C0079419
27392220	371	376	c-Myc	T116,T123	C0314684
27392220	399	410	eradication	T045	C2248542